Insider Selling: Kalvista Pharmaceuticals Inc (KALV) Major Shareholder Sells 214,198 Shares of Stock

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) major shareholder Life Sciences Fund Iv (Gp) Sv sold 214,198 shares of the stock in a transaction on Thursday, February 21st. The shares were sold at an average price of $20.55, for a total value of $4,401,768.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Life Sciences Fund Iv (Gp) Sv also recently made the following trade(s):

  • On Monday, January 7th, Life Sciences Fund Iv (Gp) Sv sold 4,299 shares of Kalvista Pharmaceuticals stock. The shares were sold at an average price of $20.25, for a total value of $87,054.75.
  • On Wednesday, December 19th, Life Sciences Fund Iv (Gp) Sv sold 2,136 shares of Kalvista Pharmaceuticals stock. The shares were sold at an average price of $20.02, for a total value of $42,762.72.

Shares of KALV stock traded up $0.81 on Thursday, hitting $20.81. 314,489 shares of the stock were exchanged, compared to its average volume of 61,865. The company has a market capitalization of $348.82 million, a price-to-earnings ratio of -13.60 and a beta of 2.38. Kalvista Pharmaceuticals Inc has a one year low of $7.73 and a one year high of $25.57.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Friday, December 14th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.24. The company had revenue of $5.59 million during the quarter, compared to the consensus estimate of $3.70 million. Kalvista Pharmaceuticals had a negative return on equity of 29.46% and a negative net margin of 84.47%. On average, analysts predict that Kalvista Pharmaceuticals Inc will post -1.78 EPS for the current fiscal year.

A number of research analysts have issued reports on the company. BidaskClub downgraded Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 7th. TheStreet upgraded Kalvista Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Thursday, December 20th. Jefferies Financial Group assumed coverage on Kalvista Pharmaceuticals in a research note on Tuesday, October 30th. They issued a “buy” rating and a $30.00 price objective for the company. Zacks Investment Research upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research note on Wednesday, January 2nd. Finally, Cantor Fitzgerald set a $32.00 price objective on Kalvista Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, November 12th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $26.00.

Several hedge funds have recently bought and sold shares of the company. Weiss Multi Strategy Advisers LLC grew its stake in shares of Kalvista Pharmaceuticals by 2.5% during the 4th quarter. Weiss Multi Strategy Advisers LLC now owns 41,000 shares of the specialty pharmaceutical company’s stock worth $810,000 after acquiring an additional 1,000 shares during the period. Barclays PLC grew its stake in shares of Kalvista Pharmaceuticals by 88,319.7% during the 4th quarter. Barclays PLC now owns 62,778 shares of the specialty pharmaceutical company’s stock worth $1,240,000 after acquiring an additional 62,707 shares during the period. Telemetry Investments L.L.C. grew its stake in shares of Kalvista Pharmaceuticals by 55.5% during the 4th quarter. Telemetry Investments L.L.C. now owns 24,883 shares of the specialty pharmaceutical company’s stock worth $491,000 after acquiring an additional 8,883 shares during the period. Polar Capital LLP bought a new position in shares of Kalvista Pharmaceuticals during the 4th quarter worth $1,558,000. Finally, Geode Capital Management LLC increased its position in Kalvista Pharmaceuticals by 30.6% during the fourth quarter. Geode Capital Management LLC now owns 83,881 shares of the specialty pharmaceutical company’s stock valued at $1,656,000 after acquiring an additional 19,636 shares during the last quarter. Institutional investors own 74.12% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Kalvista Pharmaceuticals Inc (KALV) Major Shareholder Sells 214,198 Shares of Stock” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2019/02/21/insider-selling-kalvista-pharmaceuticals-inc-kalv-major-shareholder-sells-214198-shares-of-stock.html.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: S&P 500 Index

Insider Buying and Selling by Quarter for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit